In-vitro metabolism of GW1516 and implementation of its major metabolites in routine doping controls

Ines Möller, Andreas Thomas, Simon Beuck, Grigory Rodchenkov, Wolfgang Bornatsch, Hans Geyer, Wilhelm Schänzer, Mario Thevis

Publikation: Beitrag in Buch/Bericht/KonferenzbandKonferenzbeitrag - Aufsatz in KonferenzbandForschung

Abstract

The PPARδ-agonist GW1516 is categorized as a gene doping substance by the World Anti-Doping Agency due to its upregulation of genes associated with oxidative metabolism and a modified substrate preference potentially resulting in an improved athletic performance. To enable the detection of abuse in sport via analysis of urine specimens, the phase-I and -II metabolism of GW1516 was simulated by an in-vitro assay. Two oxygenated metabolites (sulfoxide and sulfone) were identified as main phase-I metabolites as well as one hydroxylation and the respective monoglucuronides of GW1516 and the oxygenated metabolites as phase-II metabolites. As the sulfoxide and the sulfone were both excreted in urine, they were chosen as target analytes and successfully implemented in routine doping control procedures. Verf.-Referat
OriginalspracheDeutsch
TitelRecent advances in doping analysis (18) : Proceedings of the Manfred-Donike-Workshop, 28th Cologne Workshop on Dope Analysis : 7th to 12th March 2010
Herausgeber*innenWilhelm Schänzer, Hans Geyer, A. Gotzmann, Ute Mareck
Seitenumfang10
Herausgeber (Verlag)Sportverlag Strauß
Erscheinungsdatum2010
Seiten17-26
PublikationsstatusVeröffentlicht - 2010
VeranstaltungCologne Workshop on Dope Analysis - Köln, Deutschland
Dauer: 07.03.201012.03.2010
Konferenznummer: 28

Fachgebiete und Schlagwörter

  • Doping
  • Dopinganalyse
  • Dopingbekämpfung
  • Dopingkontrolle
  • Dopingnachweis
  • Gendoping
  • Metabolit

Zitation